Head & Neck Cancers

ACCC Creates Resources for Multidisciplinary Practices to Prepare for Growing Geriatric Cancer Population

February 25, 2020

To help clinicians cope with an increasing number of geriatric patients with cancer, the Association of Community Cancer Centers is address­ing this problem with a 2-pronged approach that focuses on the delivery of care and diagnostic assessment.

FDA Grants Fast Track Designation to NBTXR3 in Locally Advanced Head and Neck Cancers

February 11, 2020

An FDA Fast Track Designation was granted to the first-in-class radioenhancer NBTXR3 with or without cetuximab for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy, according to a press release from Nanobiotix.

Lenvatinib/Pembrolizumab Shows Promising Antitumor Activity and Safety in Select Solid Tumors

January 30, 2020

In a phase II trial, the combination of lenvantinib and pembrolizumab demonstrated a manageable safety profile and encouraging antitumor activity in patients with selected advanced solid tumors. The decision to combine the agents was based on preclinical data, which suggested that VEGF and FGF signaling may enhance the therapeutic efficacy of lenvatinib.

First Randomized Clinical Trial Evaluating Geriatric Assessment Reveals High Satisfaction With Communication About Aging-Related Concerns

January 18, 2020

Integrating a geriatric assessment into the care of older adults who are receiving cancer treatment in communi­ty oncology practices improves patient and caregiver satisfaction and encourages commu­nication about aging-related concerns, accord­ing to results of a clinical trial that enrolled 541 patients with advanced cancer.

Telehealth Delivers Access to Care and Cutting-Edge Clinical Research to Rural Areas

January 11, 2020

The present and future benefits of telehealth in oncology can be observed through Tahoe For­est Cancer Center and its affiliation with the UC Davis Cancer Center, use of other remote clinics, and participation in virtual tumor boards. Even though there are roadblocks to telehealth reaching more locations and more patients, the potential benefit warrants the time needed to get over those hurdles.

MRTX849 Shows Safety, Tolerability in Treating KRAS G12C

November 29, 2019

In patients whose solid tumors harbor a mutation in KRAS G12C, therapy with MRTX849 has produced promising responses and acceptable toxicity across 3 tumors types, according to data presented at the 2019 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics.

Emerging Data in R/R DLBCL

November 04, 2019

Non-Hodgkin Lymphoma

FDA Approves New Aprepitant Dosing Regimen for CINV After MEC

October 23, 2019

The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.

Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCL

October 07, 2019

Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.

ASCO Adds Oral Anticoagulants to Venous Thromboembolism Guidelines for Patients With Cancer

October 04, 2019

The addition of direct oral oral anticoagulants for the management of venous thromboembolism in patients with cancer is the latest change to previous guidelines issued by the American Society of Clinical Oncology.